Inhaled dry powder treprostinil (liq861) (DrugBank: Treprostinil)
6 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
51 | 全身性強皮症 | 0 |
84 | サルコイドーシス | 0 |
85 | 特発性間質性肺炎 | 0 |
86 | 肺動脈性肺高血圧症 | 1 |
88 | 慢性血栓塞栓性肺高血圧症 | 0 |
210 | 単心室症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03884465 (ClinicalTrials.gov) | November 11, 2019 | 4/3/2019 | Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil | A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Subjects | Pulmonary Arterial Hypertension | Drug: Inhaled dry powder treprostinil (LIQ861) | Liquidia Technologies, Inc. | FGK Clinical Research GmbH | Recruiting | 18 Years | N/A | All | 32 | Phase 2 | France;Germany |